

APPLICANT(S): YEDGAR, Saul et al.
SERIAL NO.: 10/627,981
FILED: July 28, 2003
Page 4

REMARKS

Claims 1-7 and 19-22 are pending in the application. Claims 1-7 and 19-22 have been rejected. New claims 23-25 have been added. Support for new claims 23-25 can be found throughout the application as originally filed on page 8 paragraph 122 and on page 9 paragraph 142. Claim 1 has been amended. Support for amended claim 1 can be found throughout the application as originally filed, for example on page 9 paragraph 145. Applicants respectfully assert that no new matter has been added.

The Telephone Interview

Applicants thank the Examiner, Peter G. O'Sullivan for indicating in a telephone conference that claims 1-7 and 19-22, are allowable, if the claims are amended to indicate that the linkage between the lipid or phospholipid and glycosaminoglycan components is an amide or ester linkage.

35 U.S.C. 103(a) Rejection

In the Office Action, the Examiner rejected claims 1-7 and 19-22 under 35 U.S.C. 103(a) as allegedly being obvious in view of the combined teaching of Yedgar et al., US 5,064,817, Chaikof et al., US 6,171,614, and Aoki et al., US 5,470,578, in view of Pruzanski et al., US 6,043,231, Sorgente et al., US 6,162,787, and Falk et al. US 6,022,866. Applicants disagree.

The claimed invention is directed to a method of treating a subject suffering from sepsis, comprising the step of administering to a subject a lipid or phospholipid moiety bonded to a glycosaminoglycan (GAG) via an amide or ester linkage. As described in the Applicants' previous response to office action of August 31, 2005, none of the compounds described in Yedgar, Chaikof, Aoki, Pruzanski, Sorgente, and Falk is the compound of the instant invention and none of the uses described are the uses of the instant invention. Applicants have herein amended the claims to refer to the linkage between the lipid or phospholipids and glycosaminoglycan, further highlighting the unique aspects of the claimed compounds for use. Accordingly, Applicants request withdrawal of the rejection.

APPLICANT(S): YEDGAR, Saul et al.

SERIAL NO.: 10/627,981

FILED: July 28, 2003


Page 5

In view of the foregoing amendments and remarks, the pending claims are deemed to be allowable. Their favorable reconsideration and allowance is respectfully requested.

Should the Examiner have any question or comment as to the form, content or entry of this Amendment, the Examiner is requested to contact the undersigned at the telephone number below. Similarly, if there are any further issues yet to be resolved to advance the prosecution of this application to issue, the Examiner is requested to telephone the undersigned counsel.

Please charge any fees associated with this paper to deposit account No. 50-3355.

Respectfully submitted,



Rachel Teitelbaum
Agent for Applicants
Registration No. 56,708

Dated: March 6, 2006

Pearl Cohen Zedek Latzer, LLP

1500 Broadway, 12th Floor

New York, New York 10036

Tel: (646) 878-0800

Fax: (646) 878-0801